Tarsus Pharmaceuticals, Inc. (TARS) financials

Tarsus Pharmaceuticals, Inc. (TARS) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Tarsus Pharmaceuticals, Inc. reported revenue of $451M, up 146.7% year over year, net income of -$66M, diluted EPS of -$1.59 and free cash flow of -$22M.

Revenue (fiscal 2025)

$451M

Revenue growth (fiscal 2025)

146.7%

Net income (fiscal 2025)

-$66M

Diluted EPS (fiscal 2025)

-$1.59

Free cash flow (fiscal 2025)

-$22M

Tarsus Pharmaceuticals, Inc. files with the U.S. Securities and Exchange Commission under CIK 0001819790, classified as Biological Products, (No Diagnostic Substances).

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.